Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both ...

US biotech Iovance Biotherapeutics is cutting 19% of its workforce due to slower-than-expected launch of its ...

Iovance Biotherapeutics, headquartered in the Bay Area and pioneering a new type of cancer treatment, is laying off about a ...

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) ...

Novo Nordisk falls as company slashes 2025 forecasts as US sales of Wegovy and Ozempic face headwinds from compounded drugs.

US senator Ron Wyden is demanding that the Department of Homeland Security investigate reports of agents being reassigned to ...

Akeso announces China NMPA accepts sNDA for ivonescimab in combo with chemotherapy to treat advanced squamous NSCLC: Honk Kong Tuesday, July 29, 2025, 16:00 Hrs [IST] Akeso, Inc., ...

AngioDynamics has enrolled the first subject in the AMBITION BTK trial designed to assess the Auryon Atherectomy System.

NANJING, China, July 25, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" ...

Along with the money challenge, messaging will be an issue for GOP candidates as Pritzker and his Democratic Party will blame ...

Based Topicals to Largest Medical Cannabis Market in the USA VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / July 29, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC:OVATF) ("Ovation" or the "Company") ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...